Clinical Neurology and Neurosurgery
Volume 112, Issue 6 , Pages 467-469 , July 2010

Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases

Received 4 May 2009 ,Revised 15 January 2010 ,Accepted 16 February 2010.

References 

  1. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve. 1996;19:388–391
  2. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–728
  3. Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol. 2008;21:358–365
  4. Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–1231
  5. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3:36–44
  6. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–144
  7. Anonymous . NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA. 1990;264:3189–3193
  8. Ferrero B, Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol Sci. 2002;23(Suppl. 1):S9–24
  9. Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol. 2003;10:11–16
  10. Sinclair CJ, Brooks W, Genereux MG. Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. Biologicals. 2008;36:256–262
  11. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 1994;97(Suppl. 1):79–83
  12. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–262
  13. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders—a prospective study. J Neurol. 2003;250:818–821
  14. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–841
  15. Tufan F, Kamali S, Erer B, Gul A, Inanc M, Ocal L, et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol. 2007;26:1913–1915
  16. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:S13–21
  17. Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov. 2008;3:141–144
  18. Caress JB, Cartwright MS, Donofrio PD, Peacock JE. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60:1822–1824
  19. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21:171–185
  20. Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology. 2001;57:1699–1701

PII: S0303-8467(10)00052-1

doi: 10.1016/j.clineuro.2010.02.008

Clinical Neurology and Neurosurgery
Volume 112, Issue 6 , Pages 467-469 , July 2010

Article Tools